Mr. Chair, from a Health Canada regulatory perspective, the vaccine has been approved for people 18 and up. That's what creates the legal framework for its use. The only contraindication is people who had a vaccine-induced thrombotic event with thrombocytopenia associated with their first dose. They are not recommended to use it for their second dose. Beyond that, as Dr. Tam has noted, the guidance on optimal use of the vaccine is provided by the National Advisory Committee on Immunization.
On April 30th, 2021. See this statement in context.